EYEPOINT, INC.
Last · —$3.01-0.06 (-1.95%)live · yahoo · 1h ago
Vol 3.16M ≈ 9.50M
MA10MA20MA50
Market cap$259.50M—
P/E · TTM—fwd — · eps —
Beta—vs S&P 500
Div yield—annual · TTM
52w range
——
Volume—session
Issuer
Legal nameEYEPOINT, INC.
HQUnited States (US)
ListingUS EYPT
ISINUS30233G2093
SectorHealthcare
IndustryPharmaceuticals
SIC3826
CurrencyUSD
Entity registrysec:0001314102
CIK0001314102
Websitewww.eyepoint.bio
Employees214
AddressEyePoint Pharmaceuticals, Inc. 480 Pleasant Street 02472, Watertown +617 926 5000
| Revenue | $31.4M |
|---|---|
| Operating income | $-243.4M |
| Net income | $-232.0M |
| Free cash flow | $-243.4M |
| Operating margin | -776.0% |
| Net margin | -739.4% |
| Return on equity | -75.8% |
| Period | 2025 |
Loading chart…
OpenFilings analyst
Our analyst
10-K · 2026-03-05
From latest 10-K · 2026-03-05
- Sbc Revenue High
- Operating Cf Burn
- Net Margin Sharply Negative
- Cash Conversion Weak
- Cash Runway Low
- Accumulated Deficit High
- Rd Intensity High
Red flags
- Sbc Revenue High — SBC/Revenue 88.8%
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -739.4%
- Cash Conversion Weak — Cash conversion (CFO/Rev) -765.4%
- Cash Runway Low — Cash runway ~0.4 years
- Accumulated Deficit High — Accumulated deficit / equity 361%
- Rd Intensity High — R&D/Revenue 704.6%
Upcoming earnings
WED.4NOV
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.92
Est. revenue
252,500
Press & signals
- GlobeNewswire
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- GlobeNewswire
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- GlobeNewswire
EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags
Showing 5 of 118 filings